Adaptogenics Appoints Accomplished Peptide Scientist Dr. J. David Warren as Chief Executive Officer
Adaptogenics Health Corp. (CSE: ADPT) appointed peptide scientist Dr. J. David Warren as CEO and director effective October 1, 2026, replacing Anthony Franco.
Key figures
- Option term
- three years
- Equity plan max
- 20% of issued and outstanding common shares
- Options granted
- 800000
- Option exercise price
- $0.10
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.